<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MCO</journal-id>
<journal-title-group>
<journal-title>Molecular and Clinical Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2049-9450</issn>
<issn pub-type="epub">2049-9469</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mco.2018.1575</article-id>
<article-id pub-id-type="publisher-id">MCO-0-0-1575</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Management consideration for patient with a large solitary fibrous tumor occupying the infratemporal fossa: A case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Adachi</surname><given-names>Makoto</given-names></name>
<xref rid="af1-mco-0-0-1575" ref-type="aff">1</xref>
<xref rid="af2-mco-0-0-1575" ref-type="aff">2</xref>
<xref rid="c1-mco-0-0-1575" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Motohashi</surname><given-names>Masayuki</given-names></name>
<xref rid="af1-mco-0-0-1575" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Kaku</surname><given-names>Yasuhiko</given-names></name>
<xref rid="af3-mco-0-0-1575" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Sugie</surname><given-names>Shigeyuki</given-names></name>
<xref rid="af4-mco-0-0-1575" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Muramatsu</surname><given-names>Yasunori</given-names></name>
<xref rid="af1-mco-0-0-1575" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Sumitomo</surname><given-names>Shinichiro</given-names></name>
<xref rid="af2-mco-0-0-1575" ref-type="aff">2</xref></contrib>
</contrib-group>
<aff id="af1-mco-0-0-1575"><label>1</label>Department of Oral and Maxillofacial Surgery, Asahi University Murakami Memorial Hospital, Gifu 500-8523, Japan</aff>
<aff id="af2-mco-0-0-1575"><label>2</label>Department of Oral and Maxillofacial Surgery, Division of Oral Pathogenesis and Disease Control, Asahi University, School of Dentistry, Mizuho, Gifu 501-0296, Japan</aff>
<aff id="af3-mco-0-0-1575"><label>3</label>Department of Neurosurgery, Asahi University Murakami Memorial Hospital, Gifu 500-8523, Japan</aff>
<aff id="af4-mco-0-0-1575"><label>4</label>Department of Pathology, Asahi University Murakami Memorial Hospital, Gifu 500-8523, Japan</aff>
<author-notes>
<corresp id="c1-mco-0-0-1575"><italic>Correspondence to</italic>: Dr Makoto Adachi, Department of Oral and Maxillofacial Surgery, Division of Oral Pathogenesis and Disease Control, Asahi University, School of Dentistry, 1851 Hozumi, Mizuho, Gifu 501-0296, Japan, E-mail: <email>madachi_dds_phd@yahoo.co.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2018</year></pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>02</month>
<year>2018</year></pub-date>
<volume>8</volume>
<issue>4</issue>
<fpage>544</fpage>
<lpage>548</lpage>
<history>
<date date-type="received"><day>09</day><month>11</month><year>2017</year></date>
<date date-type="accepted"><day>22</day><month>12</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Adachi et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>The solitary fibrous tumor (SFT) was first described as a mesenchymal tumor of fibroblastic type, present in the pleura. The head and neck area is the third most common site of SFT occurrence. Numb chin syndrome (NCS) is a rare neurological symptom. The current report describes the case of a 39-year-old female patient referred to the present hospital with NCS, which was later observed to be due to a large SFT in the infratemporal fossa. Computed tomography and magnetic resonance images were taken and subsequent examination of these images revealed a space occupying mass (52&#x00D7;50&#x00D7;40 mm) in the infratemporal fossa. An open biopsy was performed on the lower part of the right auricula following angiography assisted vascular embolization of the maxillary artery. Pathological diagnosis was verified as SFT. Despite the tumor size and anatomical site, the SFT was successfully reduced in size by treatment with intensity modulated radiation therapy (IMRT) alone, with no recurrence. IMRT treatment of SFT may be effective as a future potential option for locally advanced head and neck SFT.</p>
</abstract>
<kwd-group>
<kwd>solitary fibrous tumor</kwd>
<kwd>numb chin syndrome</kwd>
<kwd>intensity modulated radiation therapy</kwd>
<kwd>infratemporal fossa</kwd>
<kwd>vascular tumor</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Solitary fibrous tumors (SFT), a rare mesenchymal neoplasm originally described in the pleura by Klempere and Rabin in 1931 (<xref rid="b1-mco-0-0-1575" ref-type="bibr">1</xref>), are uncommon spindle cell neoplasms of mesenchymal origin, but more recently reported at a wide range of anatomic sites.</p>
<p>Hemangiopericytoma (HPC) is a very rare vascular tumor and originates from small pericapillary spindle cells called Zimmermann&#x0027;s pericytes, which was first described by Stout and Murray in 1942 as a tumor of the retroperitoneum, buttock, and thigh (<xref rid="b2-mco-0-0-1575" ref-type="bibr">2</xref>). HPC has been considered as a cellular variant of SFT. In the 2013 World Health Organization (WHO) classification of tumors of the soft tissue, HPC was removed as a synonym for SFT (<xref rid="b3-mco-0-0-1575" ref-type="bibr">3</xref>).</p>
<p>The predilection sites of this tumor are the lower limbs, axilla, and pelvis as well as the head and neck (<xref rid="b4-mco-0-0-1575" ref-type="bibr">4</xref>). The head and neck area is the third most common site, accounting for 15&#x2013;30&#x0025; of all occurrences. In the head and neck region, the tumor usually involves the orbit, nasal cavity, oral cavity, jaw, parotid gland, parapharyngeal space or jugular foramen (<xref rid="b5-mco-0-0-1575" ref-type="bibr">5</xref>).</p>
<p>Numb chin syndrome (NCS) is a rare neurological symptom and an indicator of various diseases. It describes a condition presenting as orofacial sensory disturbance especially localized to the lower lip and chin. The condition manifests spontaneously without history of trauma, infection or obvious dental cause. NCS is an important finding as it may be the initial symptom of Multiple Sclerosis or metastatic malignancy (<xref rid="b6-mco-0-0-1575" ref-type="bibr">6</xref>).</p>
<p>In this paper, we report a case of a large SFT in the infratemporal fossa which manifested NCS as the initial symptom, and was treated with intensity modulated radiation therapy alone.</p>
</sec>
<sec sec-type="cases">
<title>Case report</title>
<p>An otherwise healthy 39-year-old female patient was referred to our hospital having experienced right lower lip numbness for one month. She had no past medical history. Initial findings indicated no facial swelling or trismus. Intra-oral findings revealed no abnormal observation. Panoramic radiography showed that there were no bony lesions at the mandible. However, the right lower wisdom tooth showed signs of pericoronitis (<xref rid="f1-mco-0-0-1575" ref-type="fig">Fig. 1</xref>). The patient received medication with antibiotics and Vitamin B12 to improve the pericoronitis and right lower lip numbness. Two weeks following referral, in spite of these medications, right lower lip numbness was not improved. Three months later, the right lower wisdom tooth was extracted, and subsequently right lower lip numbness was slightly improved.</p>
<p>At five months post referral the lower part of the right auricula displayed swelling. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a space occupying mass (52&#x00D7;50&#x00D7;40 mm) in the infratemporal fossa (<xref rid="f2-mco-0-0-1575" ref-type="fig">Figs. 2</xref> and <xref rid="f3-mco-0-0-1575" ref-type="fig">3</xref>). Fine needle aspiration biopsy (FNAB) was performed at this site and hemoid gelatinous fluid was withdrawn. However, pathological examination of the sample did not lead to final diagnosis. Parotid gland tumor, neurilemoma, primitive neuroectodermal tumor (PNET), conventional HPC, and SFT were cited as differential diagnoses.</p>
<p>An open biopsy was performed on the lower part of the right auricula following angiography assisted vascular embolization of the maxillary artery (<xref rid="f4-mco-0-0-1575" ref-type="fig">Fig. 4A and B</xref>). The tumor was found in deeper layers than the parotid gland, and bleeding was not observed during biopsy due to the effect of vascular embolization (<xref rid="f4-mco-0-0-1575" ref-type="fig">Fig. 4C</xref>). Immunohistologically, CD99 was positive, CD34 was positive only for vascular endothelium, and B cell lymphoma 2 (Bcl-2) was weakly positive. These findings suggested SFT. Then, athological diagnosis was confirmed as SFT (<xref rid="f5-mco-0-0-1575" ref-type="fig">Fig. 5A-H</xref>).</p>
<p>We offered the patient intensity modulated radiation therapy (IMRT) and obtained written informed consent. IMRT of the primary lesion was performed five times per week at two Gray (Gy) per fraction, for a total of 66 Gy. The treatment was continued, with radiation being administered for about six weeks. The patient developed grade two stomatitis, dry mouth, grade two dermatitis, grade two alopecia, and grade two dysgeusia (National Cancer Institute common toxicity criteria, version 4.0).</p>
<p>Successful shrinkage of the tumor was seen in MRI 3 years after treatment without recurrence (<xref rid="f6-mco-0-0-1575" ref-type="fig">Fig. 6</xref>). Slight numbness of the lower lip, trismus, occasional light dizziness and sustained tinnitus remained as problematic disorders.</p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>SFT originating in the infratemporal fossa was first described by Buchanan (<xref rid="b7-mco-0-0-1575" ref-type="bibr">7</xref>), followed by several reports showing SFT arising from the infra temporal fossa (<xref rid="b8-mco-0-0-1575" ref-type="bibr">8</xref>&#x2013;<xref rid="b10-mco-0-0-1575" ref-type="bibr">10</xref>). These case reports showed swelling in the temporal region without pain, and they did not show nerve palsy as a first manifestation. In the case presented, the patient with a huge SFT at the infratemporal fossa displayed numb chin syndrome as a first manifestation and the period from first presentation to final diagnosis took approximately 6 months. NCS is mostly caused by odontogenic lesions, commonly recognized as symptoms of Vincent&#x0027;s disease. NCS can also be caused by malignant tumor, infectious disease, degenerative disease or metabolic disease in an area supplied by the submandibular nerve (<xref rid="b6-mco-0-0-1575" ref-type="bibr">6</xref>). NCS should be differentially diagnosed not only for odontogenic diseases but also the possibility of various other causes, and sufficient image examination should be considered.</p>
<p>SFT are a heterogeneous group of rare spindle-cell tumors including benign and malignant neoplasms (<xref rid="b11-mco-0-0-1575" ref-type="bibr">11</xref>). In this case, NCS may be due to the expansion of the tumor and compression of the trigeminal nerve third branch.</p>
<p>SFT originate from mesothelial mesenchymal cells, whereas HPC originates from capillary pericytes. These tumors have much in common in clinical behavior, pathological findings and image findings. HPC is now considered to be a cellular variant of SFT. The 2006 WHO fascicle of soft tissue tumors stated the histological appearance and clinical behavior of HPC and SFT are similar, a view also shared by others (<xref rid="b12-mco-0-0-1575" ref-type="bibr">12</xref>). In the 2013 WHO classification of soft tissue tumors, the terminology is unified as SFT only (<xref rid="b13-mco-0-0-1575" ref-type="bibr">13</xref>). In the case presented, the tumor was diagnosed as HPC by histopathological examination including immunostaining, but it was difficult to distinguish from SFT using image findings alone.</p>
<p>The standard treatment of SFT is still controversial. The optimal treatment for SFT is considered to be radical resection of the tumor (<xref rid="b14-mco-0-0-1575" ref-type="bibr">14</xref>). SFT is considered to be a radiosensitive tumor (<xref rid="b10-mco-0-0-1575" ref-type="bibr">10</xref>). The combination of radical surgery and post-operative radiation therapy was suggested to reduce the rate of local recurrence (<xref rid="b15-mco-0-0-1575" ref-type="bibr">15</xref>). Cytotoxic chemotherapy such as doxorubicin-based, gemcitabine-based, and paclitaxel-based are used for patients with locally advanced, recurrent, or metastatic SFT, and show a poor response (<xref rid="b16-mco-0-0-1575" ref-type="bibr">16</xref>). Recent novel targeted agents such as temozolomide-bevacizumab combination therapy (<xref rid="b17-mco-0-0-1575" ref-type="bibr">17</xref>), sunitinib (<xref rid="b18-mco-0-0-1575" ref-type="bibr">18</xref>), sorafenib (<xref rid="b19-mco-0-0-1575" ref-type="bibr">19</xref>), pazopanib (<xref rid="b20-mco-0-0-1575" ref-type="bibr">20</xref>) and anti-insulin-like growth factor I agents (<xref rid="b21-mco-0-0-1575" ref-type="bibr">21</xref>) showed more favorable results than conventional cytotoxic chemotherapy in advanced SFT patients. In our case, we opted for a single treatment by IMRT to the SFT at the infratemporal fossa because surgical access may be difficult as this area includes the lower cranial nerve, internal carotid artery, and internal jugular vein.</p>
<p>Despite the tumor size and anatomical site, tumor shrinkage was obtained successfully without relapse/recurrence. IMRT alone may be effective as a future potential treatment option for locally advanced head and neck SFT.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mco-0-0-1575"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemperer</surname><given-names>P</given-names></name><name><surname>Rabin</surname><given-names>C</given-names></name></person-group><article-title>Primary neoplasms of the pleura. A report of five cases</article-title><source>Am J Ind Med</source><volume>22</volume><fpage>1</fpage><lpage>31</lpage><year>1992</year><pub-id pub-id-type="doi">10.1002/ajim.4700220103</pub-id><pub-id pub-id-type="pmid">1415270</pub-id></element-citation></ref>
<ref id="b2-mco-0-0-1575"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname><given-names>AP</given-names></name><name><surname>Murray</surname><given-names>MR</given-names></name></person-group><article-title>Hemangiopericytoma: A vascular tumor featuring zimmermann&#x0027;s pericytes</article-title><source>Ann Surg</source><volume>116</volume><fpage>26</fpage><lpage>33</lpage><year>1942</year><pub-id pub-id-type="doi">10.1097/00000658-194207000-00004</pub-id><pub-id pub-id-type="pmid">17858068</pub-id></element-citation></ref>
<ref id="b3-mco-0-0-1575"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>LA</given-names></name></person-group><article-title>Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone</article-title><source>Cancer</source><volume>120</volume><fpage>1763</fpage><lpage>1774</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/cncr.28657</pub-id><pub-id pub-id-type="pmid">24648013</pub-id></element-citation></ref>
<ref id="b4-mco-0-0-1575"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>GP</given-names></name><name><surname>Yoon</surname><given-names>SS</given-names></name></person-group><article-title>Malignant tumors of blood vessels: Angiosarcomas, hemangioendotheliomas, and hemangioperictyomas</article-title><source>J Surg Oncol</source><volume>97</volume><fpage>321</fpage><lpage>329</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/jso.20973</pub-id><pub-id pub-id-type="pmid">18286475</pub-id></element-citation></ref>
<ref id="b5-mco-0-0-1575"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fareed</surname><given-names>MM</given-names></name><name><surname>Al Amro</surname><given-names>AS</given-names></name><name><surname>Akasha</surname><given-names>R</given-names></name><name><surname>Al Assiry</surname><given-names>M</given-names></name><name><surname>Al Asiri</surname><given-names>M</given-names></name><name><surname>Tonio</surname><given-names>M</given-names></name><name><surname>Bayoumi</surname><given-names>Y</given-names></name></person-group><article-title>Parapharyngeal space hemangiopericytoma treated with surgery and postoperative radiation-a case report</article-title><source>Head Neck Oncol</source><volume>4</volume><fpage>10</fpage><year>2012</year><pub-id pub-id-type="doi">10.1186/1758-3284-4-10</pub-id><pub-id pub-id-type="pmid">22480217</pub-id></element-citation></ref>
<ref id="b6-mco-0-0-1575"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RM</given-names></name><name><surname>Hassan</surname><given-names>A</given-names></name><name><surname>Robertson</surname><given-names>CE</given-names></name></person-group><article-title>Numb chin syndrome</article-title><source>Curr Pain Headache Rep</source><volume>19</volume><fpage>44</fpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s11916-015-0515-y</pub-id><pub-id pub-id-type="pmid">26210355</pub-id></element-citation></ref>
<ref id="b7-mco-0-0-1575"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>G</given-names></name></person-group><article-title>Two rare tumours involving the infratemporal fossa: Alveolar soft part sarcoma and haemangiopericytoma</article-title><source>J Laryngol Otol</source><volume>89</volume><fpage>375</fpage><lpage>389</lpage><year>1975</year><pub-id pub-id-type="doi">10.1017/S0022215100080506</pub-id><pub-id pub-id-type="pmid">1127332</pub-id></element-citation></ref>
<ref id="b8-mco-0-0-1575"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>H</given-names></name><name><surname>Miyata</surname><given-names>M</given-names></name><name><surname>Kuriki</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Ichimura</surname><given-names>K</given-names></name></person-group><article-title>Haemangiopericytoma of infratemporal fossa</article-title><source>J Laryngol Otol</source><volume>115</volume><fpage>77</fpage><lpage>79</lpage><year>2001</year><pub-id pub-id-type="doi">10.1258/0022215011906894</pub-id><pub-id pub-id-type="pmid">11233635</pub-id></element-citation></ref>
<ref id="b9-mco-0-0-1575"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brucoli</surname><given-names>M</given-names></name><name><surname>Giarda</surname><given-names>M</given-names></name><name><surname>Valente</surname><given-names>G</given-names></name><name><surname>Benech</surname><given-names>A</given-names></name></person-group><article-title>Hemangiopericytoma of the infratemporal fossa: Progression toward malignancy in a 30-year history</article-title><source>J Craniofac Surg</source><volume>16</volume><fpage>1146</fpage><lpage>1150</lpage><year>2005</year><pub-id pub-id-type="doi">10.1097/01.scs.0000180006.52986.c2</pub-id><pub-id pub-id-type="pmid">16327574</pub-id></element-citation></ref>
<ref id="b10-mco-0-0-1575"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>B</given-names></name><name><surname>Poli</surname><given-names>T</given-names></name><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Sesenna</surname><given-names>E</given-names></name></person-group><article-title>Malignant hemangiopericytoma of the infratemporal fossa: Report of a case</article-title><source>J Oral Maxillofac Surg</source><volume>60</volume><fpage>309</fpage><lpage>312</lpage><year>2002</year><pub-id pub-id-type="doi">10.1053/joms.2002.30589</pub-id><pub-id pub-id-type="pmid">11887146</pub-id></element-citation></ref>
<ref id="b11-mco-0-0-1575"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penel</surname><given-names>N</given-names></name><name><surname>Amela</surname><given-names>EY</given-names></name><name><surname>Decanter</surname><given-names>G</given-names></name><name><surname>Robin</surname><given-names>YM</given-names></name><name><surname>Marec-Berard</surname><given-names>P</given-names></name></person-group><article-title>Solitary fibrous tumors and so-called hemangiopericytoma</article-title><source>Sarcoma</source><volume>2012</volume><fpage>690251</fpage><year>2012</year><pub-id pub-id-type="doi">10.1155/2012/690251</pub-id><pub-id pub-id-type="pmid">22566753</pub-id></element-citation></ref>
<ref id="b12-mco-0-0-1575"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini-Spaltro</surname><given-names>A</given-names></name><name><surname>Eusebi</surname><given-names>V</given-names></name></person-group><article-title>Meningeal hemangiopericytomas and hemangiopericytoma/solitary fibrous tumors of extracranial soft tissues: A comparison</article-title><source>Virchows Arch</source><volume>456</volume><fpage>343</fpage><lpage>354</lpage><year>2010</year><pub-id pub-id-type="doi">10.1007/s00428-010-0888-6</pub-id><pub-id pub-id-type="pmid">20165866</pub-id></element-citation></ref>
<ref id="b13-mco-0-0-1575"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Bridge</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name></person-group><source>World Health Organization Classification of Tumours of Soft Tissue and Bone</source><publisher-name>IARC Press</publisher-name><publisher-loc>Lyon, France</publisher-loc><year>2013</year></element-citation></ref>
<ref id="b14-mco-0-0-1575"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koscielny</surname><given-names>S</given-names></name><name><surname>Br&#x00E4;uer</surname><given-names>B</given-names></name><name><surname>F&#x00F6;rster</surname><given-names>G</given-names></name></person-group><article-title>Hemangiopericytoma: A rare head and neck tumor</article-title><source>Eur Arch Otorhinolaryngol</source><volume>260</volume><fpage>450</fpage><lpage>453</lpage><year>2003</year><pub-id pub-id-type="doi">10.1007/s00405-003-0625-8</pub-id><pub-id pub-id-type="pmid">12759763</pub-id></element-citation></ref>
<ref id="b15-mco-0-0-1575"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirmer</surname><given-names>CM</given-names></name><name><surname>Heilman</surname><given-names>CB</given-names></name></person-group><article-title>Hemangiopericytomas of the skull base</article-title><source>Neurosurg Focus</source><volume>30</volume><fpage>E10</fpage><year>2011</year><pub-id pub-id-type="doi">10.3171/2011.2.FOCUS119</pub-id><pub-id pub-id-type="pmid">21529166</pub-id></element-citation></ref>
<ref id="b16-mco-0-0-1575"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Ravi</surname><given-names>V</given-names></name><name><surname>Conley</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>SR</given-names></name><name><surname>Trent</surname><given-names>JC</given-names></name><name><surname>Lev</surname><given-names>DC</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name><name><surname>Araujo</surname><given-names>DM</given-names></name></person-group><article-title>The role of chemotherapy in advanced solitary fibrous tumors: A retrospective analysis</article-title><source>Clin Sarcoma Res</source><volume>3</volume><fpage>7</fpage><year>2013</year><pub-id pub-id-type="doi">10.1186/2045-3329-3-7</pub-id><pub-id pub-id-type="pmid">23663788</pub-id></element-citation></ref>
<ref id="b17-mco-0-0-1575"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Patel</surname><given-names>SR</given-names></name><name><surname>Ludwig</surname><given-names>JA</given-names></name><name><surname>Trent</surname><given-names>JC</given-names></name><name><surname>Conrad</surname><given-names>CA</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Boonsirikamchai</surname><given-names>P</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor</article-title><source>Cancer</source><volume>117</volume><fpage>4939</fpage><lpage>4947</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/cncr.26098</pub-id><pub-id pub-id-type="pmid">21480200</pub-id></element-citation></ref>
<ref id="b18-mco-0-0-1575"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacchiotti</surname><given-names>S</given-names></name><name><surname>Negri</surname><given-names>T</given-names></name><name><surname>Palassini</surname><given-names>E</given-names></name><name><surname>Conca</surname><given-names>E</given-names></name><name><surname>Gronchi</surname><given-names>A</given-names></name><name><surname>Morosi</surname><given-names>C</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Pastorino</surname><given-names>U</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Casali</surname><given-names>PG</given-names></name><name><surname>Pilotti</surname><given-names>S</given-names></name></person-group><article-title>Sunitinib malate and figitumumab in solitary fibrous tumor: Patterns and molecular bases of tumor response</article-title><source>Mol Cancer Ther</source><volume>9</volume><fpage>1286</fpage><lpage>1297</lpage><year>2010</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-1205</pub-id><pub-id pub-id-type="pmid">20457621</pub-id></element-citation></ref>
<ref id="b19-mco-0-0-1575"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domont</surname><given-names>J</given-names></name><name><surname>Massard</surname><given-names>C</given-names></name><name><surname>Lassau</surname><given-names>N</given-names></name><name><surname>Armand</surname><given-names>JP</given-names></name><name><surname>Le Cesne</surname><given-names>A</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name></person-group><article-title>Hemangiopericytoma and antiangiogenic therapy: Clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma/solitary fibrous tumour</article-title><source>Invest New Drugs</source><volume>28</volume><fpage>199</fpage><lpage>202</lpage><year>2010</year><pub-id pub-id-type="doi">10.1007/s10637-009-9249-1</pub-id><pub-id pub-id-type="pmid">19352594</pub-id></element-citation></ref>
<ref id="b20-mco-0-0-1575"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleijfer</surname><given-names>S</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Papai</surname><given-names>Z</given-names></name><name><surname>Le Cesne</surname><given-names>A</given-names></name><name><surname>Scurr</surname><given-names>M</given-names></name><name><surname>Sch&#x00F6;ffski</surname><given-names>P</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Pandite</surname><given-names>L</given-names></name><name><surname>Marreaud</surname><given-names>S</given-names></name><name><surname>De Brauwer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>3126</fpage><lpage>3132</lpage><year>2009</year><pub-id pub-id-type="doi">10.1200/JCO.2008.21.3223</pub-id><pub-id pub-id-type="pmid">19451427</pub-id></element-citation></ref>
<ref id="b21-mco-0-0-1575"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quek</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Morgan</surname><given-names>JA</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Butrynski</surname><given-names>JE</given-names></name><name><surname>Ramaiya</surname><given-names>N</given-names></name><name><surname>Huftalen</surname><given-names>T</given-names></name><name><surname>Jederlinic</surname><given-names>N</given-names></name><name><surname>Manola</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors</article-title><source>Clin Cancer Res</source><volume>17</volume><fpage>871</fpage><lpage>879</lpage><year>2011</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2621</pub-id><pub-id pub-id-type="pmid">21177764</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mco-0-0-1575" position="float">
<label>Figure 1.</label>
<caption><p>Panoramic radiograph. There were no bony lesions at the mandible.</p></caption>
<graphic xlink:href="mco-08-04-0544-g00.jpg"/>
</fig>
<fig id="f2-mco-0-0-1575" position="float">
<label>Figure 2.</label>
<caption><p>Computed tomography (CT) before treatment. (A) Horizontal and (B) coronal.</p></caption>
<graphic xlink:href="mco-08-04-0544-g01.tif"/>
</fig>
<fig id="f3-mco-0-0-1575" position="float">
<label>Figure 3.</label>
<caption><p>Magnetic resonance imaging (MRI) before treatment.</p></caption>
<graphic xlink:href="mco-08-04-0544-g02.tif"/>
</fig>
<fig id="f4-mco-0-0-1575" position="float">
<label>Figure 4.</label>
<caption><p>(A) Frontal view of angiography, (B) Side view of angiography, (C) intra-operating view of open biopsy.</p></caption>
<graphic xlink:href="mco-08-04-0544-g03.tif"/>
</fig>
<fig id="f5-mco-0-0-1575" position="float">
<label>Figure 5.</label>
<caption><p>Pathological findings. (A) Hematoxylin and eosin staining (original magnification, &#x00D7;10), (B) Hematoxylin and eosin staining (original magnification, &#x00D7;20). (C) CD99 staining (original magnification, &#x00D7;10), (D) CD99 staining (original magnification, &#x00D7;20), (E) CD34 staining (original magnification, &#x00D7;10), (F) CD34 staining (original magnification, &#x00D7;20), (G) Bcl-2 staining (original magnification, &#x00D7;10), (H) Bcl-2 staining (original magnification, &#x00D7;20).</p></caption>
<graphic xlink:href="mco-08-04-0544-g04.tif"/>
</fig>
<fig id="f6-mco-0-0-1575" position="float">
<label>Figure 6.</label>
<caption><p>Magnetic resonance imaging (MRI) three years after treatment.</p></caption>
<graphic xlink:href="mco-08-04-0544-g05.tif"/>
</fig>
</floats-group>
</article>
